Davenport & Co’s Corbus Pharmaceuticals CRBP Stock Holding History

Davenport & Co’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-833	Closed	-$49K	–	949
2021 Q1	$49K	Buy	+833	New	+$54.8K	﹤0.01%	792

Other funds holding CRBP

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Davenport & Co's CRBP Position: Q2 2021 in Review

Davenport & Co sold out of Corbus Pharmaceuticals (CRBP) in Q2 2021, closing a stake of 833 shares — an estimated $49K sold.

Davenport & Co first reported a position in CRBP in Q1 2021 and held it in 1 quarter. The position peaked at $49K in Q1 2021. 98 funds tracked by Wall St. Rank hold CRBP as of Q2 2021.

Davenport & Co reported no remaining Corbus Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Davenport & Co sold 833 Corbus Pharmaceuticals shares in Q2 2021, an estimated $49K.
Davenport & Co first reported a position in Corbus Pharmaceuticals in Q1 2021 and held it in 1 quarter.
Davenport & Co's Corbus Pharmaceuticals position peaked at $49K in Q1 2021.
98 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2021.

Based on Davenport & Co's 13F filing for Q2 2021, filed 21 Jul 2021.